Boston Biotech Consultants will match your unique needs to our network of consultants and associates to assure the most desired and timely successful outcome to your consulting needs and corporate goals. Boston Biotech Consultants is led by it's Senior Principle Consultant with over 25 years of biopharmaceutical and biotech experience.


Robert Carl Tuttle, Ph.D., Senior Principle Consultant

With four FDA approved human therapeutics and vaccines and eight more therapeutics  in advanced clinical trials, Dr. Robert Tuttle is widely regarded as an innovative, pioneering cell, microbiological and tissue culture biologist, with over 25 years of scientific research, commercial development, management, financial and cGMP manufacturing experience including extensive recent "Man in the Plant" oversight & troubleshooting experience.. and recently invented a method to double influenza vaccine output which is now available for license.

Previously, Dr. Tuttle served as Vice President Manufacturing for Genetix Pharmaceuticals, where he successfully led the cGMP manufacturing of the first clinical recombinant Lentivirus biologic for sickle cell anemia  gene therapy.

Between 2000 through 2004, Dr. Robert Tuttle performed pioneering medical countermeasures research in the Biodefense Medical Systems Department of the Battelle Memorial Institute.  Among significant research achievements during his tenure at Battelle, Dr. Tuttle successfully invented and patented an avian coccidiosis vaccine, and further invented the production process for a new, better, safer recombinant anthrax protective vaccine in record time for NIAAID & BARDA & manufactured the new material for testing in animals & humans that led to NIAID and BARDA contracts worth over $900 million dollars.

Dr. Robert Tuttle also served as the Director of Biologics for Novopharm Biotech between 1997 and 2000, during which time he invented processes to manufacture second entry biologics (Bio-Generics) such as TPA blood clot buster and EPO erythropoietin red blood cell stimulus and a new, better human serum albumin based formulation of paclitaxel (Taxol®) for first line cancer therapy. Taxol® is the first anti-cancer agent to surpass $500 million in US sales, and since FDA approval, has generated over $10 billion in revenues.

While at Immunomedics and Cytogen between 1991 and 1996, Dr. Robert Tuttle scaled up and manufactured six of the first clinical monoclonal antibodies in-house & at leading CMOs for in vivo colorectal, prostate and lymphoma cancer imaging and therapies. Earlier in his career, Dr. Tuttle directed manufacture and modernization of the commercial plasma proteins at CSL in Kankakee, Illinois, including the invention of much-needed PCR-grade albumin, and scaled up the first FDA-approved tissue engineered living skin equivalent at Organogenesis in Cambridge, Massachusetts.

Dr. Tuttle received his Ph.D. in molecular cellular and developmental biology from Harvard University, won three Post-Doctoral Fellowships in molecular genetics and biochemistry in Liverpool, England, Trondheim, Norway and University of California San Diego and earned a BS Honors degree in microbiology at Syracuse University.